Certain breast CA patients benefit from adjuvant capecitabine

June 1, 2017

(HealthDay)—Capecitabine (Xeloda) can extend the lives of patients with human epidermal growth factor receptor 2 (HER2)-negative breast cancer who have residual invasive disease after receipt of neoadjuvant chemotherapy, according to a study published in the June 1 issue of the New England Journal of Medicine.

The new trial focused on 910 women with HER2-negative residual invasive after neoadjuvant chemotherapy. Participants received standard post-surgical treatment either with capecitabine or without (the control group).

The researchers found that capecitabine was associated with a reduced risk of relapse or death (30 percent over five years). At that point, 74.1 percent were still alive and recurrence-free, versus 67.6 percent of women in the control group. Five years later, 89.2 percent of capecitabine patients were still alive, compared with 83.6 percent of control patients. Among women with , 78.8 percent of capecitabine patients were alive after five years, compared with 70.3 percent of control patients.

"After standard containing anthracycline, taxane, or both, the addition of adjuvant capecitabine therapy was safe and effective in prolonging disease-free survival and overall survival among patients with HER2-negative breast cancer who had residual invasive disease on pathological testing," the authors conclude.

Explore further: Capecitabine improved outcomes for breast cancer patients with disease after presurgery chemo

More information: Abstract/Full Text (subscription or payment may be required)

Related Stories

Capecitabine improved outcomes for breast cancer patients with disease after presurgery chemo

December 9, 2015
Treatment with the chemotherapy agent capecitabine increased disease-free survival for women with HER2-negative breast cancer that was not eliminated by presurgery chemotherapy, according to results from the phase III CREATE-X ...

Capecitabine monotherapy does not improve survival in elderly patients with early-stage breast cancer

December 12, 2014
In elderly breast cancer patients with moderate- to high-risk early-stage disease for whom standard chemotherapy is too toxic, the chemotherapy capecitabine, which causes fewer side effects than the standard chemotherapy ...

Study finds greater potential benefit in overall survival for eribulin compared with capecitabine

June 12, 2013
Subgroup analyses from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate, with capecitabine, a standard chemotherapy medication in women with previously treated metastatic breast cancer, ...

Axillary pCR linked to improved breast cancer survival

January 5, 2016
(HealthDay)—For women with breast cancer treated with primary systemic chemotherapy (PST), achieving axillary pathologic complete response (pCR) is associated with improved survival, according to a study published online ...

Study compares standard against newer treatment in women whose breast cancer has spread

December 7, 2012
Results from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate with capecitabine, a standard drug used for chemotherapy today in women with previously treated metastatic breast cancer, ...

Neratinib active in HER2-positive, HR-negative breast cancer

July 7, 2016
(HealthDay)—Neratinib and veliparib-carboplatin appear to be effective in women with specific subtypes of breast cancer, according to two studies published online July 6 in The New England Journal of Medicine.

Recommended for you

CAR-T immunotherapy may help blood cancer patients who don't respond to standard treatments

October 20, 2017
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers. Newly approved ...

Researchers pinpoint causes for spike in breast cancer genetic testing

October 20, 2017
A sharp rise in the number of women seeking BRCA genetic testing to evaluate their risk of developing breast cancer was driven by multiple factors, including celebrity endorsement, according to researchers at the University ...

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.